drugset / Trial / NCT02525744
A Study of a New LY900014 Formulation in Healthy Participants
RandomizedCrossoverSingle-blindBasic science
Summary
This study evaluates a new formulation of LY900014, a drug that lowers blood sugar. It is administered by injection under the skin of the abdomen. The study will be conducted in healthy people to investigate how quickly and how much LY900014 is absorbed and the effect of different doses of LY900014 on blood sugar levels. Side effects and tolerability will be documented. The study will last for about 8 to 9 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.
Timeline
- Start
- 2015-08
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Insulin Lispro | Protein / enzyme biologic | 7.5 iu | Subcutaneous |
| Comparator | Insulin Lispro | Protein / enzyme biologic | 15 iu | Subcutaneous |
| Comparator | Insulin Lispro | Protein / enzyme biologic | 30 iu | Subcutaneous |
| Comparator | Insulin Lispro | Protein / enzyme biologic | — | Subcutaneous |
Indications
No indication recorded.